Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Comparator Clear all
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

NCT03308799
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
MC2-01 cream, Cal/BDP combination, Cream vehicle
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Fridley, Minnesota • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

NCT04893486
View directory record Official record
Conditions
BCCs in Gorlin Syndrome Patients
Interventions
PTX-022, Vehicle comparator
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of EBI-005 in Dry Eye Disease

NCT01998802
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Active Comparator EBI-005, Placebo Comparator
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
45
States / cities
Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers

NCT03754465
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-DFU, Hydrogel SHEET(Vehicle control)
Biological · Procedure
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

NCT03927703
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00888914
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001, Vehicle Comparator
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Francisco, California • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 4 Interventional Results available

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

NCT02579096
View directory record Official record
Conditions
Gout, Chronic Kidney Diseases
Interventions
allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped), Placebo, vehicle control (allopurinol-shaped)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124552
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001 Botulinum toxin type A (Dose A), RT001 Botulinum Toxin Type A (Dose B), Vehicle, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 18, 2026, 1:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

NCT03954236
View directory record Official record
Conditions
Non-sclerotic Cutaneous Chronic Graft-versus-host Disease
Interventions
topical ruxolitinib 1.5% cream, Topical vehicle/moisturizer cream
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01231373
View directory record Official record
Conditions
Varicose Veins
Interventions
polidocanol injectable foam, 0.125%, polidocanol injectable foam, 0.5%, polidocanol injectable foam, 1.0%, Vehicle
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
Dothan, Alabama • San Diego, California • Lafayette, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

NCT02672332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
55
States / cities
Anaheim, California • Encinitas, California • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597
View directory record Official record
Conditions
Dry Eye Disease
Interventions
A197 Ophthalmic Solution, A197 Vehicle Control, Active Comparator
Drug
Lead sponsor
Aramis Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

NCT03064438
View directory record Official record
Conditions
Acne Rosacea
Interventions
ACCU-D1, Vehicle
Drug
Lead sponsor
Accuitis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Louisville, Kentucky • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03394677
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% ointment, Vehicle ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Los Angeles, California • Oklahoma City, Oklahoma • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02250651
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

NCT02654769
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
22
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 18, 2026, 1:50 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

NCT07426120
View directory record Official record
Conditions
Psoriasis Vulgaris, Topical Administration, Phase III
Interventions
Total coumarin (TC) cream, Vehicle cream
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187
View directory record Official record
Conditions
Genital Warts, Perianal Warts
Interventions
NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Fountain Valley, California • Lomita, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

NCT01072877
View directory record Official record
Conditions
Varicose Veins
Interventions
Polidocanol injectable foam (PEM), Placebo Vehicle
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
20
States / cities
Laguna Hills, California • San Diego, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 18, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

NCT03445013
View directory record Official record
Conditions
Psoriasis
Interventions
SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Boise, Idaho • Austin, Texas • College Station, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 18, 2026, 1:50 AM EDT